Investigational Drug Details
| Drug ID: | D366 |
| Drug Name: | Thiazolidinediones |
| Synonyms: | TZD; Thiazolidinedione |
| Type: | Chemical drug |
| DrugBank ID: | DB11898 |
| DrugBank Description: | Thiazolidinedione has been investigated for the treatment of Type 2 Diabetes, Diabetes Mellitus, and DIABETES MELLITUS, TYPE 2. |
| PubChem ID: | 5437 |
| CasNo: | 2295-31-0 |
| Repositioning for NAFLD: | No |
| SMILES: | O=C1NC(=O)SC1 |
| Structure: |
|
| InChiKey: | ZOBPZXTWZATXDG-UHFFFAOYSA-N |
| Molecular Weight: | 117.129 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 4 on-going (NCT03646292) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0050 | NCT03646292 | Phase 4 | Recruiting | No Results Available | December 19, 2018 | October 19, 2020 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | Details |
| A00475 | 35068786 | J Clin Exp Hepatol | Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study. | Details |
| A00656 | 35013417 | Sci Rep | Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver. | Details |
| A00724 | 34988690 | Acta Diabetol | Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. | Details |
| A01118 | 34863942 | Mol Metab | The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease. | Details |
| A01673 | 34659439 | Evid Based Complement Alternat Med | Ginsenoside Re Improves Inflammation and Fibrosis in Hepatic Tissue by Upregulating PPARγ Expression and Inhibiting Oxidative Stress in db/db Mice. | Details |
| A01741 | 34630909 | World J Diabetes | Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. | Details |
| A01808 | 34607257 | Biochem Biophys Res Commun | The alleviating effect of sphingosine kinases 2 inhibitor K145 on nonalcoholic fatty liver. | Details |
| A01948 | 34557367 | Cureus | Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. | Details |
| A02326 | 34417811 | Endocrinology | Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity. | Details |
| A02850 | 34219361 | Liver Int | PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. | Details |
| A03104 | 34129693 | Hepatology | Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. | Details |
| A03385 | 34022222 | J Biol Chem | Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. | Details |
| A03626 | 33925827 | Int J Mol Sci | Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. | Details |
| A03740 | 33882758 | Expert Rev Clin Pharmacol | Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. | Details |
| A03861 | 33841337 | Front Endocrinol (Lausanne) | Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis. | Details |
| A03995 | 33798599 | Eur J Pharmacol | Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | Details |
| A04933 | 33444819 | Cell Mol Gastroenterol Hepatol | Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver. | Details |
| A05137 | 33359401 | Mol Metab | Insulin resistance is mechanistically linked to hepatic mitochondrial remodeling in non-alcoholic fatty liver disease. | Details |